<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599324</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1128-CA</org_study_id>
    <nct_id>NCT02599324</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors</brief_title>
  <official_title>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of single
      agent ibrutinib or the combination treatments of ibrutinib with everolimus, paclitaxel,
      docetaxel, pembrolizumab or cetuximab in selected advanced gastrointestinal and genitourinary
      tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: To determine the recommended Phase 2 dose (RP2D) of ibrutinib</measure>
    <time_frame>Approximately 6 months after evaluation</time_frame>
    <description>Evaluated by the number of dose-limiting toxicities (DLT) graded using the NCI CTCAE v 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: To assess progression-free survival (PFS)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Defined by the time from the date of first dose of study drug until confirmed disease progression based on investigator assessment, per RECIST 1.1, or death from any cause, whichever comes first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: To assess the overall response rate (ORR)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Defined by the proportion of subjects with a best response of complete response (CR) or partial response (PR) by investigator assessment, per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of ibrutinib combination or single agent</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Safety and tolerability of ibrutinib combination or single agent as measured by frequency and type of adverse events graded using NCI CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the disease control rate (DCR).</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Defined by the proportion of subjects with a best response of complete response (CR), partial response (PR), stable disease (greater than or equal to 6 weeks) by investigator assessment, per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: To assess the duration of response (DOR)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Defined for responders as duration of time from initial response (CR or PR by investigator assessment) to first documentation of disease progression or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: To assess the median overall survival (OS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Defined as the time from first dose of study drug to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <condition>Advanced Urothelial Carcinoma</condition>
  <condition>Advanced Gastric Adenocarcinoma</condition>
  <condition>Metastatic Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Renal Cell Carcinoma - Enrollment Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with everolimus to determine the Recommended Phase 2 Dose (RP2D) of ibrutinib.
Phase 2: Patients will receive ibrutinib at the RP2D determined in Phase 1b in combination with everolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urothelial Carcinoma - Enrollment Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with paclitaxel to determine the RP2D of ibrutinib.
Phase 2: Subjects will receive paclitaxel at the RP2D determined in Phase 1b in combination with paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric Adenocarcinoma - Enrollment Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with docetaxel to determine the RP2D of ibrutinib.
Phase 2: Subjects will receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colorectal Adenocarcinoma - Enrollment Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with cetuximab to determine RP2D of ibrutinib.
Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urothelial Carcinoma Ibrutinib- Enrollment Closed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urothelial Carcinoma with Pembrolizumab - Recruiting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with pembrolizumab to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Colorectal Adenocarcinoma - Enrollment Closed</arm_group_label>
    <arm_group_label>Gastric Adenocarcinoma - Enrollment Closed</arm_group_label>
    <arm_group_label>Renal Cell Carcinoma - Enrollment Closed</arm_group_label>
    <arm_group_label>Urothelial Carcinoma - Enrollment Closed</arm_group_label>
    <arm_group_label>Urothelial Carcinoma Ibrutinib- Enrollment Closed</arm_group_label>
    <arm_group_label>Urothelial Carcinoma with Pembrolizumab - Recruiting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Renal Cell Carcinoma - Enrollment Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Gastric Adenocarcinoma - Enrollment Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Urothelial Carcinoma - Enrollment Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Colorectal Adenocarcinoma - Enrollment Closed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Urothelial Carcinoma with Pembrolizumab - Recruiting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RCC (clear cell), urothelial carcinoma (UC) (transitional cell), gastric or
             gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR
             expressing CRC

          -  For cohort 1 RCC: minimum of 1 and maximum of 4 prior regimens, one or more of which
             must have included a VEGF-TKI

          -  For UC cohort 2: minimum of 1 and maximum of 2 prior regimens, one of which must have
             included a platinum-based regimen

          -  For UC cohort 5: Minimum of 1 and maximum of 2 prior regimens, one of which must have
             included a checkpoint inhibitor.

          -  For UC cohort 6:

               -  Locally advanced or mUC who are not eligible for cisplatin chemo with a PDL-1
                  score (CPS) of ≥ 10 without prior treatment.

               -  Locally advanced or mUC who have progressed on platinum chemo or within 12 months
                  of neo- or adjuvant therapy with a platinum chemotherapy. A minimum of 1 and
                  maximum of 2 prior therapies.

          -  For cohort 3 gastric or GEJ adenocarcinoma: minimum of 1 and maximum of 3 prior
             regimens one of which must have included a fluoropyrimidine regimen

          -  For cohort 4 CRC: minimum of 2 and maximum of 4 prior regimens, which must have
             included both an irinotecan and an oxaliplatin based regimen unless unable to tolerate
             irinotecan chemotherapy

        Laboratory:

          -  Adequate hematologic function:

               -  Absolute neutrophil count ≥1500 cells/mm3 (1.5 x 109/L)

               -  Platelet count &gt;80,000 cells/mm3 (80 x 109/L) for cohort 1 (RCC)

               -  Platelet counts &gt;100,000 cells/mm3 (100 x 109/L) for all UC cohorts

               -  Hemoglobin ≥8.0 g/dL. for cohort 1 (RCC),all UC cohorts, and cohort 3 (GC)

               -  Hemoglobin ≥9.0 g/dL for cohort 4 (CRC)

          -  Adequate hepatic and renal function defined as:

               -  Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤5.0 x upper

               -  limit of normal (ULN) if liver metastases, or ≤3 x ULN without liver metastases

               -  Alkaline phosphatase &lt;3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present

               -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of
                  non-hepatic

               -  origin, such as hemolysis) with the exception of subjects in the GC cohort where

               -  docetaxel is administered, these subjects must have bilirubin within normal
                  limits (WNL)

               -  Estimated Creatinine Clearance ≥30 mL/min (Cockcroft-Gault)

        Exclusion Criteria

          -  Prior treatment with:

               -  Everolimus or temsirolimus (RCC cohort 1)

               -  Any taxane (UC cohort of ibrutinib + paclitaxel) (cohort 2)

               -  Checkpoint inhibitors (UC cohort 6)

               -  Any taxane (GC cohort 3)

               -  Cetuximab or panitumumab (CRC cohort 4)

          -  For all Cohorts:

               -  Concomitant use of warfarin or other Vitamin K antagonists

               -  History of stroke or intracranial hemorrhage within 6 months prior to enrollment

               -  Major surgery within 4 weeks of first dose of study drug

               -  Requires treatment with strong CYP3A inhibitors known bleeding disorders or
                  hemophilia

          -  UC cohort 6 only:

               -  Subjects who have an active, known or suspected autoimmune disease.

               -  Evidence of clinically significant interstitial lung disease or active,
                  noninfectious pneumonitis.

               -  Non-steroid immunosuppressive medications within 14 days before the first dose of
                  ibrutinib and pembrolizumab.

               -  Subjects in whom prior anti PD-1 / anti-PD-L1 therapy was intolerable and
                  required discontinuation of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Indu Lal, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics, an AbbVie Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kalyan Obalampalli</last_name>
    <phone>+1650-407-3191</phone>
    <email>PCYC-1128-CA@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0965</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Centre</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0802</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center - Bannor Hospital</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1546</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0209</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Helena Hospital</name>
      <address>
        <city>Saint Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0419</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #969</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1085</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph Health</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1462</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Whittingham Cancer Center at Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1093</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, Inc</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitas and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0766</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0706</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>East Jefferson General Hospital</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1084</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0130</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0195</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Care Cancer Center</name>
      <address>
        <city>Bolivar</city>
        <state>Missouri</state>
        <zip>65613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1596</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Capital Region Medical Center, Goldschmidt Cancer Center</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1412</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0229</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Hematology Oncology Associates (NJHOA)</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0493</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Juan Oncology Associates</name>
      <address>
        <city>Farmington</city>
        <state>New Mexico</state>
        <zip>87401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0402</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0024</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch (UTMB) - Cancer Center</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Washington/Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1382</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital and Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0894</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #916</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #982</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #926</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0927</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #963</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0925</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0928</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #924</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla (HUMV)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0973</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0534</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0533</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala D'Oncologia Badalona</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0984</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0874</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0864</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0921</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio (HUVR)</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0863</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0543</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Center</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0652</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #1079</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0030</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator #0814</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

